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Breast cancer is the most common malignant tumour that 
affects women around the world.
Roughly one in eight woman suffers from breast cancer 
during her lifetime, and the average age of women with 
breast cancer has declined over the years. The European 
Society of Breast Imaging (EUSOBI) and 30 national breast 
radiology bodies support mammography for population-
based screening, which has been shown to reduce breast 
cancer mortality and treatment impact (1). Considering 
the evidence from several cohort and case-control studies, 
the International Agency for Research on Cancer (IARC) 
showed its support for screening mammography as well 
(2), however the available data did not allow the IARC 
working group to define an optimal screening interval. 
Most European countries opted for biennial screening in 
the 50- to 69-year-old cohort, and annual interval for the 
40- to 49-year-old cohort, giving the potential for higher 
BC growth rates and lower mammography sensitivity in 
presence of higher breast density. (1) Current breast cancer 
screening guidelines recommend a general starting age for 
screening for all women, including those at increased risk, 
such as those with a family history of breast cancer. Based 
on expert opinion rather than empirical evidence, American 
Cancer Society guidelines recommend starting breast 
cancer screening at age 40 years or 10 years before the 
youngest relative with a breast cancer diagnosis. 
In a recent study published in JAMA Oncology, Mukama 
et al. pointed out that the age-oriented screening approach 
that pays little attention to individual risks is sub-optimal 
and that personalized screening should be advocated (3). 
The aim of his paper, titled “Risk-Adapted Starting Age 
of Screening for Relatives of Patients with Breast Cancer” is 
to identify the risk-adapted starting age of breast cancer 
screening on the basis of a woman’s detailed family history. 
This nationwide cohort study analyzed data recorded in 
Swedish family-cancer datasets. Data from January 1,1958, 
to December 31, 2015, were collected and analyzed from 
October 1, 2017, to March 31, 2019. Patients population 
included 5,099,172 women born from 1,932 onward and 
with at least 1 known first degree relative (FDR) with a 
breast cancer diagnosis. Risk-adapted starting age of breast 
cancer screening varied by the number of affected first-
or second-degree relatives and by age at diagnosis of first-
degree relatives. In this model women with multiple affected 
first-degree relatives reached the screening risk level at age 
27 to 36 years, depending on the youngest age at diagnosis 
in relatives; while mass screening was recommended at 
age 50 years. The risk-adapted starting age is similar to 
the starting age suggested by the American College of 
Radiology, which age is 30 years or 10 years earlier than the 
youngest relative with a breast cancer diagnosis. However, 
as the authors state, selecting other ages at diagnosis in 
relatives, the differences could be even greater, from –6 
to +24 years, than observed. It has been established that 
screening for high risk women should be started earlier, 
but is mammography the best imaging approach to screen 
women with above-average risk? Considering that, as 
the authors explain, tumours in young women tend to be 
biologically more aggressive and are associated with poor 
survival and that young women generally have dense breast 
and screening mammography does not work well. 
Recently Vaughan wrote a review on new imaging 
approaches in screening. In addition to full-field digital 
mammography (FFDM), nine other imaging modalities 
have been identified for review (4). Of these, those suitable 
for young women since they do not expose the patient to 
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ionizing radiation and are applicable as a screening tool in 
terms of sensitivity and specificity, are magnetic resonance 
imaging (MRI); automated breast ultrasound (ABUS) and 
tactile sensor imaging. From a screening point of view, as 
Vaughan said, MRI has four main disadvantages compared 
to mammography: long examination time; need for contrast 
agent; poor specificity; and cost of the equipment. In fact, 
with regard to the low specificity of MRI, in a recent article, 
Kuhl (5) argued that the positive predictive value (PPV)
for MRI is the same as that of mammographic screening. 
In addition, recent literature data have reported increasing 
evidence that abbreviated screening protocol can be an 
interesting way to reduce MRI costs for acquisition and 
reading time in the screening setting. The original Kuhl 
and co-authors protocol (6) consisted of a single T1-
weighted gradient-echo sequence before the Gadolinium-
based contrast agent (GBCA) injection, repeated after the 
injection, for a total acquisition time of only 3 minutes. 
Thereafter, many studies (7-12) confirmed that the 
diagnostic performance of the abbreviated protocols was 
not significantly reduced compared to a standard full 
protocol, with a drastically reduced reading time (12,13). 
However, a limitation of abbreviated protocols may be 
the lack of biomarker information, provided by functional 
techniques (14). This perspective should be favored 
in the case of a general acceptance of the use of CE 
MRI for the screening of women with medium or at 
least intermediate-risk women. However, the recent 
controversy over the potential dangers associated with 
Gd retention in the brain after repeated administrations 
of GBCAs, has raised doubts about MRI screening of 
healthy women outside of those who have a real high-
risk profile. Future large prospective studies will clarify 
the scenarios for the use of abbreviated contrast-enhanced 
(CE) MRI protocols in the screening setting, also in 
combination with DWI as an option without contrast (15). 
Although DWI lacks the spatial resolution of dynamic 
CE MRI, several groups of researchers are optimistic that 
recent technical advances in DWI will lead to improved 
sensitivity (16,17).
The evidence on supplemental ultrasound (US) long-
term benefits in screening is limited, even if data literature 
demonstrate that US has high sensitivity for cancer 
detection, especially in younger women with dense breast 
tissue, in early-stage invasive cancers and reduces the 
frequency of interval cancers (18). From a screening point 
of view hand-held ultrasound (HHUS) is a suboptimal 
technique as it is time-consuming and, since its operator-
dependency, it suffers from repeatability problems. In the 
past 15 years, dedicated ABUS devices have been developed 
to overcome the limitations of HHUS. In the face of 
the unique display mode, imaging features and artifacts 
in ABUS, which differ from those in HHUS, ABUS has 
exceeded mentioned HHUS limits. A recent review by Kim 
et al. shows that screening ABUS yielded a high diagnostic 
performance, similar to screening HHUS. As he reported 
supplemental ABUS screening increased breast cancer 
detection by 1.9–7.7 cases per 1,000 women; sensitivity 
increased by 21.6–41.0%, but specificity varied (18). The 
SomoInsight Study, a multicenter study conducted between 
2009 and 2011 on a total of 15,318 women, additionally 
detected 1.9 cases of breast cancer per 1000 women (19), 
which was similar to the results of Japan Strategic Anti-
cancer Randomized Trial (J-START) (20), but lower than 
the results of American College of Radiology Imaging 
Network 6,666 (21). Differences in the cancer detection 
rate are probably related to the different inclusion criteria. 
The SomoInsight study had an invasive cancers rate of 
93.3%, mean breast lesion size of 12.9 mm, and proportion 
of node-negative cancers of 92.6% (19), which were 
similar to the results of HHUS screening (20,21). ABUS 
screening was effective in detecting small, invasive, and 
predominantly node-negative breast cancers, similar to 
HHUS screening. Despite the promising results, there are 
insufficient evidence for reduction in mortality with US and 
ABUS screening at the moment, so no recommendations 
have been established for the screening guidelines. 
However, the American College of Radiology (ACR) states 
that supplemental US screening is an option for women 
with dense breasts and supplemental magnetic resonance 
imaging may be performed depending on risk factors, such 
as a history of lobular carcinoma in situ in women with 
intermediate risk for breast cancers (22). An interesting 
future direction for screening will be the fusion of FFDM 
or digital breast tomosynthesis (DBT) and ABUS in a single 
platform; although literature data are currently lacking, 
fusion techniques seem to be the next logical step in the 
screening evolution.
Another promising tool for early detection of breast 
cancer in countries with limited resources is the iBreastExam 
(iBE) (4): a tactile sensors which has secured both CE mark 
and FDA approvals. It is based on the principle of piezo-
electric detectors that generate quantitative information on 
tissue compression and stiffness, as breast cancer tumours 
tend to be hard and stiff compared to normal breast tissue. 
There are just two clinical trials (23,24) testing iBE showing 
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that the sensitivity and specificity are >80%, confirming the 
device’s potential as a low-cost screening tool. Certainly 
further researches are needed to validate these results and 
be able to introduce iBEas a widespread screening tool. 
Breast radiologists currently face challenging decisions 
in terms of choosing the right exam for breast screening, 
starting age and risk stratification based on personal risk 
factors (familiarity, ethnicity, mutations, breast density, 
lifestyle...), since most current screening programs rely on 
mammography at similar time intervals. These programs 
suggest annual or biennial mammography for all women, 
and consequently they are not clearly optimized for the 
detection of cancer on an individual level. The goal is to 
establish woman individual risk, as Pace and Keating said 
“the net benefit of screening depends greatly on baseline 
breast cancer risk, which should be in corporate into 
screening decision” (25). The study by Mukama et al. is 
in line with this statement, but the number of first and 
second degree family members and their age of tumour 
onset are sufficient to change the screening starting age? 
There are many other risk factors, including ethnicity, that 
help stratify risk and therefore change the starting age of 
screening. The main limitations of Mukama’s work are 
that it is based on the only Swedish population, and that it 
considers only familial risk, while other risk factors are not 
investigated.
A variety of empiric and mathematical risk assessment 
models based on personal and familial risk factors have been 
developed to estimate a woman’s risk of developing breast 
cancer, these models base their respective risk estimations 
on different aspects of a woman’s personal and familial 
history and thus, are not equally well calibrated for all 
populations (26).
To date there are three types of risk modeling: estimation 
from pedigree data of the probability of carrying one or 
more high-risk mutations, using segregation analysis (Claus, 
BOADICEA, BRCAPRO); a regression model for cancer 
risk based on a number of risk factors (Gail, Gail with 
polygenic risk added , Gail with breast density added, Breast 
Cancer Surveillance Consortium (BCSC) model, BCSC 
model with SNPs added, iCARE); combination of the first 
two types models (Tyrer-Cuzick, Tyrer-Cuzick with density 
and polygenic risk added). Risk models differ because 
they have been developed for different populations, use 
different risk factors and may have different assumptions 
on the effect of risk factors (Tyrer-Cuzick is calibrated to 
breast cancer rates in the UK; the Gail model to rates in the 
United States).
In a recent article Dembrower et al. has developed 
a risk model that is based on a deep neural network, 
finding inherent advantages compared to other methods 
such as visual evaluation of mammographic density 
by the radiologist who may not be able to acquire all 
the information relevant to the risk in the image. The 
authors concluded that a deep neural network trained 
on mammographic screening images and breast cancer 
outcome can more accurately predict which women are 
at risk for future breast cancer than can density-based 
models, with lower false-negative rates for more aggressive 
cancers (27).
In conclusion risk prediction is a fundamental element 
of an individually adapted screening policy and artificial 
intelligence has the potential to improve risk prediction 
and guide future screening towards personalized medicine. 
Considering the individual characteristics of each subject for 
disease susceptibility and biology and developing imaging 
biomarkers that incorporate both phenotypic and genotypic 
metrics, it is therefore possible to better stratify patients for 
more precise therapeutic care.
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